https://www.openbell.ai/ 2026-10-16T18:51:20.136Z hourly 1.0 https://www.openbell.ai/support 2026-10-16T18:51:20.136Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-16T18:51:20.136Z monthly 0.5 https://www.openbell.ai/terms 2026-10-16T18:51:20.136Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-16T18:51:20.136Z hourly 0.8 https://www.openbell.ai/news/SMCI:1792176489496 2026-10-16T18:48:09.496Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Supermicro.jpg?width=250&height=187 Super Micro Finally Names a CFO, Nearly Two Years After an Accounting Review Prompted the Search Super Micro Computer Inc. has appointed Mark Long as its new Chief Financial Officer, effective immediately, nearly two years after initiating the search due to accounting scrutiny. Long replaces David Weigand, who will now focus on optimizing the business. The company's stock fell nearly 10% following the announcement, and it faces ongoing challenges related to governance and export controls, while strong demand for AI infrastructure supports a revenue outlook of $65 billion to $72 billion for fiscal 2027. https://www.openbell.ai/news/LITE:1792176328568 2026-10-16T18:45:28.568Z daily 0.9 https://cdn.brandfetch.io/LITE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of fiber-optic connectivity companies are trading lower as elevated Treasury yields and increased Fed rate-hike expectations following this week's latest inflation data weigh on technology stocks. Elevated borrowing costs could pressure AI infrastructure spending plans, raising concerns about future demand for fiber-optic equipment and connectivity solutions. openbell Financial News https://www.openbell.ai/news/NVDA:1792175641574 2026-10-16T18:34:01.574Z daily 0.9 https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud SemiAnalysis Pots On X "SHOCKING: We have confirmed that multiple Neoclouds have been refused access to GTC Berlin due to them adding AMD GPUs, TPUs, and other chips to their cloud offerings. Note that this doesn't apply to hyperscalers, as they have more buying power. But for neoclouds, executives feel NVIDIA has been using high-pressure tactics to keep them NVIDIA-only...." Multiple neoclouds have been denied access to GTC Berlin after incorporating AMD GPUs, TPUs, and other chips into their offerings, as confirmed by SemiAnalysis. This situation does not affect hyperscalers, who possess greater buying power. Executives from the neoclouds allege that NVIDIA is employing high-pressure tactics to maintain its exclusivity in the market. https://www.openbell.ai/news/AGCC:1792175365175 2026-10-16T18:29:25.175Z daily 0.9 https://cdn.brandfetch.io/AGCC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Agencia Comercial Spirits shares are trading higher after the company announced its subsidiary AGCC Singapore entered into a long-term AI computing agreement in Indonesia. openbell Financial News https://www.openbell.ai/news/DAL:1792175308531 2026-10-16T18:28:28.531Z daily 0.9 https://cdn.brandfetch.io/DAL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of airline companies are trading lower amid a rise in oil prices. Elevated fuel costs and rising Treasury yields are fueling concerns about persistent inflation and increased financing costs, which could pressure airline profitability and weigh on passenger demand. openbell Financial News https://www.openbell.ai/news/AAL:1792175062988 2026-10-16T18:24:22.988Z daily 0.9 https://cdn.brandfetch.io/AAL/w/400/h/400?c=1idopYfmtR7ZKg8QMud American Airlines Group shares are trading lower after UBS lowered its price target on the stock from $17 to $16. openbell Financial News https://www.openbell.ai/news/WSC:1792174927895 2026-10-16T18:22:07.895Z daily 0.9 https://cdn.brandfetch.io/WSC/w/400/h/400?c=1idopYfmtR7ZKg8QMud UBS Maintains Neutral on WillScot Holdings, Lowers Price Target to $18 UBS analyst Joshua Chan has maintained a Neutral rating on WillScot Holdings (NASDAQ: WSC) and has lowered the price target from $29 to $18. This adjustment reflects a change in the analyst's outlook on the company's stock performance. https://www.openbell.ai/news/AVBP:1792174901266 2026-10-16T18:21:41.266Z daily 0.9 https://cdn.brandfetch.io/AVBP/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target BTIG analyst Jeet Mukherjee has reiterated a Buy rating on ArriVent BioPharma (NASDAQ: AVBP) and has maintained a price target of $29 for the stock. https://www.openbell.ai/news/RHHBY:1792174844706 2026-10-16T18:20:44.706Z daily 0.9 https://cdn.brandfetch.io/RHHBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy Roche Holdings AG received FDA approval for Enspryng (satralizumab), the first at-home subcutaneous treatment for thyroid eye disease. The approval was based on Phase 3 SatraGO trials, where Enspryng showed a 52.9% proptosis response rate and a 60.7% reduction in double vision among treated patients, significantly outperforming the placebo group. Following the announcement, Roche's stock price increased by 0.93% to $57.31. https://www.openbell.ai/news/SHOP:1792174844271 2026-10-16T18:20:44.271Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/The-Shopify-Trade.jpg?width=250&height=187 Shopify Price Hikes Signal Pricing Power as JPMorgan Keeps $200 Bullish Target Shopify Inc. has increased the pricing for its Grow and Advanced plans by 13% ($10) and 20% ($60), respectively, as reported by JPMorgan. Analyst Bryan Smilek estimates these changes could generate over $40 million in incremental annualized revenue, assuming a global rollout. Despite a recent 4.51% drop in stock price to $170.11, JPMorgan maintains a bullish price target of $200, reflecting confidence in Shopify's pricing power and market position. Wall Street anticipates third-quarter earnings of 46 cents per share and revenue of $3.75 billion, up from $2.84 billion a year earlier. https://www.openbell.ai/news/EW:1792174843966 2026-10-16T18:20:43.966Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Irvine--California---7-May-2023-Edwards-.jpg?width=250&height=187 FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death The FDA has issued a high-risk alert regarding a recall of specific lots of Edwards Lifesciences Corp.'s Commander M delivery systems after reports of balloons bursting during procedures, which led to one patient death and a serious injury. The company has advised customers to immediately stop using the affected products and remove them from inventory. As a result of the recall, Edwards Lifesciences' stock price fell by 0.86% to $87.34. https://www.openbell.ai/news/RHHBY:1792174824888 2026-10-16T18:20:24.888Z daily 0.9 https://cdn.brandfetch.io/RHHBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy Roche Holdings AG received FDA approval for Enspryng (satralizumab), the first at-home subcutaneous treatment for thyroid eye disease. The approval was based on Phase 3 SatraGO trials, where the SatraGO-2 trial showed a 52.9% proptosis response rate in treated patients compared to 23.4% for placebo, and a 60.7% reduction in double vision versus 25.8% in the control group. Following the announcement, Roche's stock price increased by 0.93% to $57.31. https://www.openbell.ai/news/RHHBY:1792174788907 2026-10-16T18:19:48.907Z daily 0.9 https://cdn.brandfetch.io/RHHBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy Roche Holdings AG has received FDA approval for Enspryng (satralizumab), the first at-home subcutaneous therapy for thyroid eye disease. The approval is based on the Phase 3 SatraGO trials, where the SatraGO-2 trial showed a 52.9% proptosis response rate in treated patients, compared to 23.4% for the placebo. Roche shares rose 0.93% to $57.31 following the announcement. https://www.openbell.ai/news/EW:1792174786788 2026-10-16T18:19:46.788Z daily 0.9 https://cdn.brandfetch.io/EW/w/400/h/400?c=1idopYfmtR7ZKg8QMud FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death Edwards Lifesciences Corp. (NYSE: EW) has issued a recall for specific lots of its Commander M delivery systems following reports of balloons bursting during procedures, which have resulted in one patient death and a serious injury. The FDA has flagged this as a high-risk alert, advising customers to stop using the affected products immediately. As a result of the recall, Edwards Lifesciences shares fell 0.86% to $87.34. https://www.openbell.ai/news/TSLA:1792174783009 2026-10-16T18:19:43.009Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Elon-Musk.jpg?width=250&height=187 Tesla's Flying Roadster Sends Delivery Odds Tumbling Despite Spectacular Demo Tesla Inc. (NASDAQ: TSLA) showcased its long-awaited flying Roadster, but delivery predictions have significantly decreased, with market odds for delivery by the end of 2027 dropping from 33% to around 10%. Production is not set to begin until 2028, and the company continues to accept $50,000 reservations without a guaranteed delivery date. Following the demonstration, Tesla shares initially rose over 4% in premarket trading but later fell below the previous day's closing price. https://www.openbell.ai/news/RHHBY:1792174766680 2026-10-16T18:19:26.680Z daily 0.9 https://cdn.brandfetch.io/RHHBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy Roche Holdings AG received FDA approval for Enspryng (satralizumab), the first at-home subcutaneous treatment for thyroid eye disease. The approval was based on Phase 3 SatraGO trials, where the SatraGO-2 trial showed a 52.9% proptosis response rate in treated patients, compared to 23.4% for placebo, and a 60.7% reduction in double vision versus 25.8% in the control group. Following the announcement, Roche's shares rose by 0.93% to $57.31. https://www.openbell.ai/news/AMD:1792174760895 2026-10-16T18:19:20.895Z daily 0.9 https://cdn.brandfetch.io/AMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of semiconductor and chip companies are trading lower as rising inflation concerns and elevated energy prices fuel expectations for further Fed rate hikes. Elevated borrowing costs could pressure semiconductor manufacturing and AI infrastructure investments while straining customer budgets. The Philadelphia Semiconductor Index (SOX) has declined for seven consecutive trading sessions, matching its longest losing streak since the 2008 financial crisis. openbell Financial News https://www.openbell.ai/news/EW:1792174753707 2026-10-16T18:19:13.707Z daily 0.9 https://cdn.brandfetch.io/EW/w/400/h/400?c=1idopYfmtR7ZKg8QMud FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death The FDA issued a high-risk recall alert for specific lots of Edwards Lifesciences Corp.'s Commander M delivery systems after reports of balloons bursting during procedures, leading to one death and a serious injury. The devices are used to implant replacement mitral heart valves without open-chest surgery, and the company has instructed customers to stop using the affected lots immediately. As a result of the recall, Edwards Lifesciences shares fell by 0.86% to $87.34. https://www.openbell.ai/news/GNRC:1792174565439 2026-10-16T18:16:05.439Z daily 0.9 https://cdn.brandfetch.io/GNRC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of data center infrastructure-related companies are trading lower as elevated oil prices and stronger-than-expected inflation data this week fuel concerns that interest rates will remain higher for longer. Elevated financing costs could slow investment in data centers and power infrastructure, weighing on demand for electrical equipment and HVAC systems. openbell Financial News https://www.openbell.ai/news/BA:1792174030264 2026-10-16T18:07:10.264Z daily 0.9 https://cdn.brandfetch.io/BA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Reuters Reported Federal Aviation Administration Set To Approve Boeing 737 MAX 10 As Soon As Next Week openbell Financial News https://www.openbell.ai/news/SHLS:1792173674712 2026-10-16T18:01:14.712Z daily 0.9 https://cdn.brandfetch.io/SHLS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shoals Technologies Group shares are trading lower after Mizuho lowered its price target on the stock from $11 to $10. openbell Financial News https://www.openbell.ai/news/MAN:1792173427334 2026-10-16T17:57:07.334Z daily 0.9 https://cdn.brandfetch.io/MAN/w/400/h/400?c=1idopYfmtR7ZKg8QMud ManpowerGroup shares are trading lower after multiple analysts lowered their respective price targets on the stock. openbell Financial News https://www.openbell.ai/news/COP:1792173259912 2026-10-16T17:54:19.912Z daily 0.9 https://cdn.brandfetch.io/COP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Shares of oil and gas-related companies are trading higher after reports suggesting that Iran placed its armed forced on high alert for 72 hours. Also, reports of an attempted Houthi strike on Saudi Arabia's Red Sea port of Yanbu and another Iranian strike on a vessel near the Strait of Hormuz may fuel concerns that high energy prices may persist and benefit the sector. openbell Financial News https://www.openbell.ai/news/AAPG:1792173144932 2026-10-16T17:52:24.932Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Acute-Myeloid-Leukemia-Is-A-Subtype-Of-B.jpg?width=250&height=187 Ascentage Pharma Stock Could More Than Double: Analyst Ascentage Pharma Group International (NASDAQ: AAPG) has been given an Outperform rating by analyst Alethia Young from William Blair, who initiated coverage with a valuation of $31 per share. The company is expected to reach three major clinical milestones in 2027 for its cancer treatments, olverembatinib and lisaftoclax, with estimated peak sales of $1.5 billion and $2.7 billion respectively. As of the latest report, Ascentage's stock was up 4.22% at $15.31. https://www.openbell.ai/news/EAT:1792173135652 2026-10-16T17:52:15.652Z daily 0.9 https://cdn.brandfetch.io/EAT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Raymond James Upgrades Brinker International to Strong Buy, Lowers Price Target to $260 Raymond James analyst Brian Vaccaro has upgraded Brinker International (NYSE: EAT) from Outperform to Strong Buy. However, the price target has been lowered from $270 to $260. https://www.openbell.ai/news/CORZ:1792173124336 2026-10-16T17:52:04.336Z daily 0.9 https://cdn.brandfetch.io/CORZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Core Scientific shares are trading lower after Cantor Fitzgerald lowered its price target on the stock from $39 to $30. openbell Financial News https://www.openbell.ai/news/FRMI:1792172981520 2026-10-16T17:49:41.520Z daily 0.9 https://cdn.brandfetch.io/FRMI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Fermi shares are trading lower after Cantor Fitzgerald lowered its price target on the stock from $12 to $8. openbell Financial News https://www.openbell.ai/news/MCK:1792172790641 2026-10-16T17:46:30.641Z daily 0.9 https://cdn.brandfetch.io/MCK/w/400/h/400?c=1idopYfmtR7ZKg8QMud UBS Maintains Buy on McKesson, Raises Price Target to $1200 UBS analyst Kevin Caliendo has maintained a 'Buy' rating on McKesson (NYSE: MCK) and increased the price target from $1080 to $1200. This adjustment reflects positive expectations for the company's performance. https://www.openbell.ai/news/ONON:1792172747145 2026-10-16T17:45:47.145Z daily 0.9 https://cdn.brandfetch.io/ONON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Raymond James Maintains Outperform on On Holding, Raises Price Target to $42 Raymond James analyst Rick Patel has maintained an 'Outperform' rating on On Holding (NYSE: ONON) and raised the price target from $38 to $42. This adjustment reflects a positive outlook for the company's performance. https://www.openbell.ai/news/FIVN:1792172517942 2026-10-16T17:41:57.942Z daily 0.9 https://cdn.brandfetch.io/FIVN/w/400/h/400?c=1idopYfmtR7ZKg8QMud UBS Maintains Buy on Five9, Raises Price Target to $48 UBS analyst Taylor McGinnis has maintained a Buy rating on Five9 (NASDAQ: FIVN) and increased the price target from $36 to $48. This adjustment reflects a positive outlook for the company's stock performance. https://www.openbell.ai/news/CAH:1792172417692 2026-10-16T17:40:17.692Z daily 0.9 https://cdn.brandfetch.io/CAH/w/400/h/400?c=1idopYfmtR7ZKg8QMud UBS Maintains Buy on Cardinal Health, Raises Price Target to $295 UBS analyst Kevin Caliendo has maintained a Buy rating on Cardinal Health (NYSE: CAH) and increased the price target from $280 to $295. This adjustment reflects a positive outlook for the company's stock performance. https://www.openbell.ai/news/QQQ:1792172373714 2026-10-16T17:39:33.714Z daily 0.9 https://cdn.brandfetch.io/QQQ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Major indices are trading lower as rising Treasury yields and hotter-than-expected inflation data this week fuel a rotation out of tech and AI-related stocks. Credit risks tied to the AI infrastructure buildout are adding to the pressure, with the VanEck Semiconductor ETF (SMH) down 8% this week, on track for its biggest weekly decline since July. openbell Financial News https://www.openbell.ai/news/USO:1792172039803 2026-10-16T17:33:59.803Z daily 0.9 https://cdn.brandfetch.io/USO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oil is trading higher after reports suggesting that Iran placed its armed forced on high alert for 72 hours. Also, reports of an attempted Houthi strike on Saudi Arabia's Red Sea port of Yanbu and another Iranian strike on a vessel near the Strait of Hormuz are adding to concerns over marine energy transport risks. openbell Financial News https://www.openbell.ai/news/KVYO:1792170939043 2026-10-16T17:15:39.043Z daily 0.9 https://cdn.brandfetch.io/KVYO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Goldman Sachs Downgrades Klaviyo to Neutral, Lowers Price Target to $20 Goldman Sachs analyst Callie Valenti has downgraded Klaviyo (NYSE: KVYO) from a Buy rating to Neutral. The price target for the stock has been reduced from $27 to $20. https://www.openbell.ai/news/CBTO:1792170893456 2026-10-16T17:14:53.456Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/3d-Rendering-Of-Exchange-Traded-Fund-etf.jpg?width=250&height=187 EXCLUSIVE: Calamos Bitcoin ETF Upside Tops 40%: Top Exec Reveals the Catch Investors Can’t Ignore Calamos Investments' Bitcoin ETF, the Calamos Bitcoin 80 Series Structured Alt Protection ETF (CBTO), has an upside cap exceeding 40% for its one-year outcome period that began on October 7, 2023. This cap has increased from a gross starting rate of 36.22% due to a slight decline in Bitcoin's value. The ETF offers 80% downside protection, meaning investors are exposed to the first 20% of losses, while two other ETFs from Calamos provide varying levels of protection. Factors such as interest rates and options pricing influence the potential returns and caps of these ETFs. https://www.openbell.ai/news/NWG:1792170661304 2026-10-16T17:11:01.304Z daily 0.9 https://cdn.brandfetch.io/NWG/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'NatWest Group Withdrew Its Markets Securities Business From The Federal Reserve Bank Of New York’s List Of Primary Dealers As The Firm Pulls Back From U.S. And European Government Bond Markets, Effective Today' - Bloomberg News NatWest Group has officially withdrawn its markets securities business from the Federal Reserve Bank of New York's list of primary dealers, effective immediately. This decision marks the firm's strategic pullback from U.S. and European government bond markets. The move reflects a significant shift in NatWest's operations in these regions. https://www.openbell.ai/news/NWG:1792170617388 2026-10-16T17:10:17.388Z daily 0.9 https://cdn.brandfetch.io/NWG/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'NatWest Group Withdrew Its Markets Securities Business From The Federal Reserve Bank Of New York’s List Of Primary Dealers As The Firm Pulls Back From U.S. And European Government Bond Markets, Effective Today' - Bloomberg News openbell Financial News https://www.openbell.ai/news/OPK:1792170551202 2026-10-16T17:09:11.202Z daily 0.9 https://cdn.brandfetch.io/OPK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Piper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4 Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on OPKO Health (NASDAQ: OPK) and raised the price target from $3 to $4. This adjustment reflects a positive outlook for the company in the market. https://www.openbell.ai/news/SKYD:1792170544527 2026-10-16T17:09:04.527Z daily 0.9 https://cdn.brandfetch.io/SKYD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bernstein Maintains Underperform on Skydance, Lowers Price Target to $6 Bernstein analyst Laurent Yoon has maintained an 'Underperform' rating on Skydance (NYSE: SKYD) and has reduced the price target from $12 to $6. This adjustment reflects a more cautious outlook on the company's performance. https://www.openbell.ai/news/RVMD:1792170482608 2026-10-16T17:08:02.608Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/Revolution-Medicines.jpg?width=250&height=187 Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow Revolution Medicines Inc. (NASDAQ: RVMD) has seen its stock surge 124% this year, with an analyst from William Blair initiating coverage with an Outperform rating and a price target of $226. The company received FDA approval for its RAS(ON) inhibitor, Rasonque, for metastatic pancreatic cancer, and the European Medicines Agency recommended its approval as well. Analyst Alethia Young forecasts $9.8 billion in revenue by 2032, primarily from non-small cell lung cancer treatments, while the stock was down 5.88% to $178.14 at the time of publication. https://www.openbell.ai/news/RVMD:1792170466556 2026-10-16T17:07:46.556Z daily 0.9 https://cdn.brandfetch.io/RVMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow Revolution Medicines Inc. (NASDAQ: RVMD) has seen its stock surge 124% this year, with an Outperform rating and a $226 price forecast from analyst Alethia Young of William Blair. The company received FDA approval for its RAS(ON) inhibitor Rasonque for metastatic pancreatic cancer in August, and the European Medicines Agency has recommended its approval as well. Young projects the company could achieve $9.8 billion in revenue by 2032, primarily from non-small cell lung cancer treatments, while ongoing studies aim to expand its applications in other cancers. https://www.openbell.ai/news/RVMD:1792170377590 2026-10-16T17:06:17.590Z daily 0.9 https://cdn.brandfetch.io/RVMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow Revolution Medicines Inc. (NASDAQ: RVMD) has seen its stock surge 124% this year, with an analyst from William Blair initiating coverage with an Outperform rating and a price target of $226. The company received FDA approval for its RAS(ON) inhibitor, Rasonque, for metastatic pancreatic cancer, and the European Medicines Agency has recommended its approval as well. Analyst Alethia Young forecasts $9.8 billion in revenue by 2032, emphasizing the potential for growth beyond pancreatic cancer, while the stock was down 5.88% to $178.14 at the time of publication. https://www.openbell.ai/news/XELB:1792170355808 2026-10-16T17:05:55.808Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=250&height=187 10 Consumer Discretionary Stocks Moving In Friday's Intraday Session On Friday, Xcel Brands (NASDAQ: XELB) saw its shares rise by 15.9% to $0.4, with a market value of $2.2 million. Other notable gainers included Agencia Comercial Spirits (NASDAQ: AGCC), which increased by 15.3% to $17.4, and FST (NASDAQ: KBSX), which rose 13.74% to $1.49. Conversely, Fly-E Group (NASDAQ: FLYE) experienced the largest decline, falling 19.2% to $2.73, while America’s Car-Mart (NASDAQ: CRMT) dropped 15.93% to $1.14. https://www.openbell.ai/news/MRKR:1792170355594 2026-10-16T17:05:55.594Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=250&height=187 12 Health Care Stocks Moving In Friday's Intraday Session On Friday, Marker Therapeutics (NASDAQ: MRKR) saw a significant stock increase of 21.2%, reaching $1.11, with a market value of $14.8 million. Other notable gainers included Alaunos Therapeutics (TCRT) up 16.56% to $2.54, and Cryo-Cell International (CCEL) rising 15.89% to $4.23. Conversely, MDxHealth (MDXH) experienced a substantial decline of 63.5%, dropping to $0.22, while Fractyl Health (GUTS) fell 58.39% to $1.73. https://www.openbell.ai/news/XCH:1792170355356 2026-10-16T17:05:55.356Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=250&height=187 12 Industrials Stocks Moving In Friday's Intraday Session On Friday, XCH shares rose by 16.9% to $2.9, with a market capitalization of $195.6 million. Other notable gainers included Phoenix Asia Holdings, up 16.23% to $18.9, and Marwynn Holdings, which increased by 13.48% to $2.19. Conversely, Robin Energy experienced a significant decline of 55.9%, dropping to $0.86, while Nuburu fell by 37.85% to $0.61. https://www.openbell.ai/news/XLAB:1792170355151 2026-10-16T17:05:55.151Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=250&height=187 12 Information Technology Stocks Moving In Friday's Intraday Session On Friday, Exascale Labs Holdings (NASDAQ: XLAB) saw its stock rise by 76.4% to $2.40, with a market value of $58.4 million. Other notable gainers included Phaos Technology Holdings (AMEX: POAS), which increased by 41.54% to $3.06, and Sangrix (NASDAQ: SGRX), which rose 35.74% to $0.93. Conversely, SMX (NASDAQ: SMX) experienced a significant drop of 46.7% to $1.92, while Republic Power Group (NASDAQ: RPGL) fell by 41.19% to $7.84. https://www.openbell.ai/news/BSVN:1792169895544 2026-10-16T16:58:15.544Z daily 0.9 https://cdn.brandfetch.io/BSVN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Piper Sandler Maintains Overweight on Bank7, Raises Price Target to $69 Piper Sandler analyst Nathan Race has maintained an Overweight rating on Bank7 (NASDAQ: BSVN) and raised the price target from $61 to $69. This adjustment reflects a positive outlook for the company in the market. https://www.openbell.ai/news/VRNS:1792169792766 2026-10-16T16:56:32.766Z daily 0.9 https://cdn.brandfetch.io/VRNS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Piper Sandler Downgrades Varonis Systems to Neutral, Lowers Price Target to $49.75 Piper Sandler analyst Rob Owens has downgraded Varonis Systems (NASDAQ: VRNS) from Overweight to Neutral. The price target for the stock has been reduced from $58 to $49.75. https://www.openbell.ai/news/PYPL:1792169694688 2026-10-16T16:54:54.688Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/16/London--Uk---August-2021-Paypal-Finance-.jpg?width=250&height=187 PayPal Teams Up with Glance to Turn AI Shopping Discovery into Instant Purchases PayPal Holdings, Inc. (NASDAQ: PYPL) has partnered with Glance, an AI-powered shopping platform, to enhance its commerce capabilities by integrating real-time product data and native checkout functionality for U.S. consumers. This collaboration allows users to discover products and complete purchases without leaving the Glance platform. PayPal is set to report quarterly earnings on October 27, with analysts expecting earnings per share of $1.31 and revenue of $8.71 billion, up from $8.42 billion a year earlier. As of the latest update, PayPal shares were trading at $57.42, reflecting a 0.45% increase. https://www.openbell.ai/news/AGCC:1792169554618 2026-10-16T16:52:34.618Z daily 0.9 https://cdn.brandfetch.io/AGCC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Agencia Commercial Spirits Secures Indonesia AI Computing Capacity Under $300M-$400M 5-Year Agreement Agencia Comercial Spirits Ltd announced a five-year agreement with a Singapore-based AI computing provider, securing access to AI computing resources in Indonesia for an estimated total cost of $300 million to $400 million. The agreement includes staged advance payments capped at $150 million to $160 million and outlines responsibilities for colocation, electricity, and maintenance costs. While the contract establishes a long-term commitment, it does not guarantee customer revenue or profitability, as deployment is contingent on various factors including delivery and acceptance procedures.